Dharshini NM

Sepsis is defined as life threatening systemic or local infection due to dysregulated host response, which can lead to organ or tissue damage or death. Hence it is necessary to monitor the disease. Due to lack of data on prescription patterns, it is essential to conduct such studies. To analyze prescribing patterns of Antimicrobial agents used in treating sepsis.: It was a Prospective and Observational study which was conducted for a period of 6 months in all the departments of Apollo multi-specialty hospital. All the patients admitted with  sepsis during the study period were  screened for the use of any Antimicrobials. Those who met the inclusion and exclusion criteria, were enrolled for the study. Therapeutic data such as name of drugs, doses, route of administration, duration & other laboratory data was collected and documented in a suitably designed data collection form. The Data was evaluated by using suitable statistical tools. Out of 146 patients, 95 patients (28.28%) were prescribed with Carbapenem. In this study, blood was majorly used as specimen. The commonly found causative organism was E.coli in 50 patients (32.17%) which largely effected females than males. Meropenem was found to be the major drug sensitive to E.coli. Septic shock and death were the major complications found. Health care professionals must understand the usage of antimicrobial agents for specific conditions in sepsis patients so as to minimize adverse drug reactions, complications, antimicrobial agent resistance and improve patient quality of life. The number of antimicrobial drugs prescribed to this group of patients must be minimized so as to reduce toxic effects, burden of resistance, to ensure effective treatment and improve patient safety.

Chronic Kidney Disease (CKD) characterized by progressive decline in Glomerular Filtration Rate (GFR), is major public health issue associated with morbidity and mortality. Anaemia is one of the most common problems causing morbidity in patients with CKD while they are on dialysis.  Erythropoietin is a major advance in the management of anaemia in CKD which stimulates erythropoiesis by increasing proliferation and maturation of erythroid progenitors and thereby treats anaemia. Prescribing pattern, effectiveness and cost of erythropoietin therapy in patients with chronic kidney disease. This was a Prospective and Observational study conducted for 06 months after obtaining IEC from Apollo Multi-Specialty Hospital, Bengaluru. Patients were enrolled based on enrolment criteria. Data were analysed using suitable statistical tool. Of 152 patients enrolled, 77 (50.65%) patients were in the age group ≥ 60 years, second generation ESAs was mostly prescribed 119(78.28%) than third 01(0.65%) and first 32(21.05%). Significant increase in Haemoglobin, RBC, PCV was observed. We have demonstrated that ESAs were prescribed majorly in Nephrology compared to medicine department. Second generation ESAs were prescribed mostly, darbepoetin alfa 40mcg were preferred over other doses. The changes in Hb, PCV and RBC were significant suggesting ESAs as effective. The side effects reported were less, common and mostly unrelated to ESAs. Based on these finding, we suggest that ESAs is prescribed majorly in Nephrology and is effective and safe in managing anaemia of CKD.